Literature DB >> 31288724

Targeting the 5-HT2C Receptor in Biological Context and the Current State of 5-HT2C Receptor Ligand Development.

Eric A Wold1, Christopher T Wild1, Kathryn A Cunningham1, Jia Zhou1.   

Abstract

Serotonin (5-HT) 5-HT2C receptor (5-HT2CR) is recognized as a critical mediator of diseaserelated pathways and behaviors based upon actions in the central nervous system (CNS). Since 5-HT2CR is a class A G protein-coupled receptor (GPCR), drug discovery efforts have traditionally pursued the activation of the receptor through synthetic ligands with agonists proposed for the treatment of obesity, substance use disorders and impulse control disorders while antagonists may add value for the treatment of anxiety, depression and schizophrenia. The most significant agonist discovery to date is the FDAapproved anti-obesity medication lorcaserin. In recent years, efforts towards developing other mechanisms to enhance receptor function have resulted in the discovery of Positive Allosteric Modulators (PAMs) for the 5-HT2CR, with several molecule series now reported. The biological significance and context for signaling and function of the 5-HT2CR, and the current status of 5-HT2CR agonists and PAMs are discussed in this review. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  5-HT2C receptor; Agonists; Allosteric modulation; Central nervous system disorders; Drug discovery; Ligand development; Neurotherapeutics; Pharmacological probes; Positive allosteric modulators; Signaling bias; Target selectivity.

Mesh:

Substances:

Year:  2019        PMID: 31288724      PMCID: PMC6761005          DOI: 10.2174/1568026619666190709101449

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  9 in total

1.  Agomelatine rescues lipopolysaccharide-induced neural injury and depression-like behaviors via suppression of the Gαi-2-PKA-ASK1 signaling pathway.

Authors:  Tian Lan; Yuhan Wu; Yulei Zhang; Shuhan Li; Zhanpeng Zhu; Liyan Wang; Xueqin Mao; Ye Li; Cuiqin Fan; Wenjing Wang; Shu Yan Yu
Journal:  J Neuroinflammation       Date:  2022-05-24       Impact factor: 9.587

Review 2.  Learning from lorcaserin: lessons from the negative clinical trial of lorcaserin to treat cocaine use disorder.

Authors:  S Stevens Negus; Matthew L Banks
Journal:  Neuropsychopharmacology       Date:  2020-08-24       Impact factor: 7.853

Review 3.  Modulation of Serotonin Receptors in Neurodevelopmental Disorders: Focus on 5-HT7 Receptor.

Authors:  Jieon Lee; Diana Avramets; Byungsun Jeon; Hyunah Choo
Journal:  Molecules       Date:  2021-06-02       Impact factor: 4.411

4.  Contribution of Corticotropin-Releasing Factor Receptor 1 (CRF1) to Serotonin Receptor 5-HT2CR Function in Amygdala Neurons in a Neuropathic Pain Model.

Authors:  Guangchen Ji; Volker Neugebauer
Journal:  Int J Mol Sci       Date:  2019-09-06       Impact factor: 5.923

Review 5.  Genotype-Phenotype Relationships and Endocrine Findings in Prader-Willi Syndrome.

Authors:  Régis Afonso Costa; Igor Ribeiro Ferreira; Hiago Azevedo Cintra; Leonardo Henrique Ferreira Gomes; Letícia da Cunha Guida
Journal:  Front Endocrinol (Lausanne)       Date:  2019-12-13       Impact factor: 5.555

6.  The 5-HT2C receptor as a therapeutic target for alcohol and methamphetamine use disorders: A pilot study in treatment-seeking individuals.

Authors:  Erin J Campbell; Yvonne Bonomo; Adam Pastor; Lisa Collins; Amanda Norman; Peter Galettis; Janice Johnstone; Andrew J Lawrence
Journal:  Pharmacol Res Perspect       Date:  2021-05

7.  Editorial: Contemporary Perspective on 5-HT2C Receptor Function and Its Pharmacological Targeting.

Authors:  Philippe De Deurwaerdère; Abdeslam Chagraoui; Kathryn A Cunningham
Journal:  Front Pharmacol       Date:  2020-11-23       Impact factor: 5.810

Review 8.  Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action.

Authors:  Mark J Millan
Journal:  Ther Adv Psychopharmacol       Date:  2022-06-30

9.  Safety and Preliminary Efficacy of Lorcaserin for Cocaine Use Disorder: A Phase I Randomized Clinical Trial.

Authors:  Sade E Johns; Lori Keyser-Marcus; Antonio Abbate; Edward Boone; Benjamin Van Tassell; Kathryn A Cunningham; Noelle C Anastasio; Justin L Poklis; Tatiana Ramey; F Gerard Moeller
Journal:  Front Psychiatry       Date:  2021-07-02       Impact factor: 4.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.